News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Micromet to Report Blinatumomab Data at 2011 American Society of Hematology Annual Meeting


11/8/2011 7:12:52 AM

ROCKVILLE, Md.--(BUSINESS WIRE)--Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that data on its lead product candidate blinatumomab (MT103) will be reported at the 53rd Annual American Society of Hematology (ASH) Annual Meeting, to be held December 10 – 13 in San Diego, California.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES